Benoît Kenda

This inventor holds 18 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Ucb Pharma, S.a., Ucb S.a., Uob Pharma, S.a.. Active years: 2005-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benoît Kenda. Retrieved from https://idiyas.com/inventor/benoit-kenda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 22.2

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 40(Granted Patents)

Location History:

La Bruyère, BE (2007 - 2010)
Emines, BE (2005 - 2013)

Company Filing History:

Years Active: 2005-2013

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8586623 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2013-11-19),

2. 8518943 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2013-08-27),

3. 8492416 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2013-07-23),

4. 8293775 - Benzoxazolone derivatives, processes for preparing them and their uses (2012-10-23),

5. 8183241 - 2-oxo-1-pyrrolidine derivatives (2012-05-22),

6. 8178533 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2012-05-15),

7. 8034958 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2011-10-11),

8. 7964593 - Indolone-acetamide derivatives, processes for preparing them and their uses (2011-06-21),

9. 7763644 - Imidazole derivatives, processes for preparing them and their uses (2010-07-27),

10. 7692028 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2010-04-06),

11. 7645887 - Indolone-acetamide derivatives, processes for preparing them and their uses (2010-01-12),

12. 7632856 - Indolone derivatives, processes for preparing them and their uses (2009-12-15),

13. 7473697 - 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders (2009-01-06),

14. 7358276 - 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2008-04-15),

15. 7244747 - Imidazole derivatives, processes for preparing them and their uses (2007-07-17),

Title: Benoît Kenda: Innovator in Pharmaceutical Chemistry

Introduction

Benoît Kenda is a notable inventor based in Emines, Belgium. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 18 patents. His work primarily focuses on developing compounds that address various neurological and movement disorders.

Latest Patents

Among his latest innovations are two key patents. The first patent involves 2-oxo-1-pyrrolidine derivatives, which are designed for use as pharmaceuticals. These compounds are particularly effective in treating neurological disorders such as epilepsy. The second patent pertains to benzoxazolone derivatives, which are also aimed at pharmaceutical applications. These derivatives are intended for the treatment of movement disorders, specifically targeting conditions like Parkinson's disease.

Career Highlights

Benoît Kenda has worked with prominent companies in the pharmaceutical industry, including UCB Pharma and UCB S.A. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in drug development.

Collaborations

Throughout his career, Kenda has collaborated with esteemed colleagues such as Philippe Michel and Bénédicte Lallemand. These partnerships have further enhanced his research and innovation capabilities.

Conclusion

Benoît Kenda's contributions to pharmaceutical chemistry are significant, particularly in the development of treatments for neurological and movement disorders. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.